FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023216413> ?p ?o ?g. }

• W2023216413 endingPage "332" @default.
• W2023216413 startingPage "324" @default.
• W2023216413 abstract "HIV-1 drug resistance monitoring in resource-poor settings is crucial due to limited drug alternatives. Recent reports of the increased prevalence of CXCR4 usage in subtype C infections may have implications for CCR5 antagonists in therapy. We investigated the prevalence of drug resistance mutations and CXCR4 coreceptor utilization of viruses from HIV-1 subtype C-infected children. Fifty-one children with virological failure during highly active antiretroviral therapy (HAART) and 43 HAART-naive children were recruited. Drug resistance genotyping and coreceptor utilization assessment by phenotypic and genotypic methods were performed. At least one significant drug resistance mutation was present in 85.4% of HAART-failing children. Thymidine analogue mutations (TAMs) were detected in 58.5% of HAART-failing children and 39.0% had ≥3 TAMs. CXCR4 (X4) or dual (R5X4)/mixed (R5, X4) (D/M)-tropic viruses were found in 54.3% of HAART-failing and 9.4% of HAART-naive children (p<0.0001); however, the HAART-failing children were significantly older (p<0.0001). In multivariate logistic regression, significant predictors of CXCR4 usage included antiretroviral treatment, older age, and lower percent CD4+ T cell counts. The majority of genotypic prediction tools had low sensitivity (≤65.0%) and high specificity (≥87.5%) for predicting CXCR4 usage. Extensive drug resistance, including the high percentage of TAMs found, may compromise future drug choices for children, highlighting the need for improved treatment monitoring and adherence counseling. Additionally, the increased prevalence of X4/D/M viruses in HAART-failing children suggests limited use of CCR5 antagonists in salvage therapy. Enhanced genotypic prediction tools are needed as current tools are not sensitive enough for predicting CXCR4 usage." @default.
• W2023216413 created "2016-06-24" @default.
• W2023216413 creator A5002270036 @default.
• W2023216413 creator A5017916044 @default.
• W2023216413 creator A5024709337 @default.
• W2023216413 creator A5040954811 @default.
• W2023216413 creator A5051935108 @default.
• W2023216413 creator A5056952810 @default.
• W2023216413 creator A5074965128 @default.
• W2023216413 creator A5076484464 @default.
• W2023216413 creator A5083564035 @default.
• W2023216413 creator A5084751362 @default.
• W2023216413 creator A5005809678 @default.
• W2023216413 date "2012-04-01" @default.
• W2023216413 modified "2023-10-18" @default.
• W2023216413 title "Drug Resistance and Coreceptor Usage in HIV Type 1 Subtype C-Infected Children Initiating or Failing Highly Active Antiretroviral Therapy in South Africa" @default.
• W2023216413 cites W1623426438 @default.
• W2023216413 cites W1900729316 @default.
• W2023216413 cites W1967320966 @default.
• W2023216413 cites W1982498479 @default.
• W2023216413 cites W1989091541 @default.
• W2023216413 cites W1989508688 @default.
• W2023216413 cites W1999048558 @default.
• W2023216413 cites W2005521407 @default.
• W2023216413 cites W2010452637 @default.
• W2023216413 cites W2027074843 @default.
• W2023216413 cites W2029246165 @default.
• W2023216413 cites W2034124132 @default.
• W2023216413 cites W2053320932 @default.
• W2023216413 cites W2081745197 @default.
• W2023216413 cites W2082737563 @default.
• W2023216413 cites W2097847166 @default.
• W2023216413 cites W2101093607 @default.
• W2023216413 cites W2101247921 @default.
• W2023216413 cites W2102741140 @default.
• W2023216413 cites W2103160360 @default.
• W2023216413 cites W2103546861 @default.
• W2023216413 cites W2104289712 @default.
• W2023216413 cites W2108256128 @default.
• W2023216413 cites W2109046728 @default.
• W2023216413 cites W2122986037 @default.
• W2023216413 cites W2125121305 @default.
• W2023216413 cites W2131418157 @default.
• W2023216413 cites W2145316347 @default.
• W2023216413 cites W2148245437 @default.
• W2023216413 cites W2162667658 @default.
• W2023216413 cites W2163400707 @default.
• W2023216413 cites W2169054534 @default.
• W2023216413 doi "https://doi.org/10.1089/aid.2011.0106" @default.
• W2023216413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3316120" @default.
• W2023216413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21819257" @default.
• W2023216413 hasPublicationYear "2012" @default.
• W2023216413 type Work @default.
• W2023216413 sameAs 2023216413 @default.
• W2023216413 citedByCount "20" @default.
• W2023216413 countsByYear W20232164132012 @default.
• W2023216413 countsByYear W20232164132014 @default.
• W2023216413 countsByYear W20232164132015 @default.
• W2023216413 countsByYear W20232164132017 @default.
• W2023216413 countsByYear W20232164132020 @default.
• W2023216413 countsByYear W20232164132021 @default.
• W2023216413 countsByYear W20232164132023 @default.
• W2023216413 crossrefType "journal-article" @default.
• W2023216413 hasAuthorship W2023216413A5002270036 @default.
• W2023216413 hasAuthorship W2023216413A5005809678 @default.
• W2023216413 hasAuthorship W2023216413A5017916044 @default.
• W2023216413 hasAuthorship W2023216413A5024709337 @default.
• W2023216413 hasAuthorship W2023216413A5040954811 @default.
• W2023216413 hasAuthorship W2023216413A5051935108 @default.
• W2023216413 hasAuthorship W2023216413A5056952810 @default.
• W2023216413 hasAuthorship W2023216413A5074965128 @default.
• W2023216413 hasAuthorship W2023216413A5076484464 @default.
• W2023216413 hasAuthorship W2023216413A5083564035 @default.
• W2023216413 hasAuthorship W2023216413A5084751362 @default.
• W2023216413 hasBestOaLocation W20232164132 @default.
• W2023216413 hasConcept C104317684 @default.
• W2023216413 hasConcept C114851261 @default.
• W2023216413 hasConcept C126322002 @default.
• W2023216413 hasConcept C129470790 @default.
• W2023216413 hasConcept C13373296 @default.
• W2023216413 hasConcept C135763542 @default.
• W2023216413 hasConcept C142462285 @default.
• W2023216413 hasConcept C151956035 @default.
• W2023216413 hasConcept C159047783 @default.
• W2023216413 hasConcept C170493617 @default.
• W2023216413 hasConcept C203014093 @default.
• W2023216413 hasConcept C2778899366 @default.
• W2023216413 hasConcept C2780035454 @default.
• W2023216413 hasConcept C2993143319 @default.
• W2023216413 hasConcept C3013748606 @default.
• W2023216413 hasConcept C31467283 @default.
• W2023216413 hasConcept C54355233 @default.
• W2023216413 hasConcept C71924100 @default.
• W2023216413 hasConcept C86803240 @default.
• W2023216413 hasConcept C98274493 @default.
• W2023216413 hasConceptScore W2023216413C104317684 @default.
• W2023216413 hasConceptScore W2023216413C114851261 @default.
• W2023216413 hasConceptScore W2023216413C126322002 @default.

• next